CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

https://www.prnewswire.com/news-releases/calcimedica-announces-presentation-of-data-from-a-preclinical-study-of-auxora-in-acute-kidney-injury-at-the-29th-international-aki–crrt-conference-302074930.html

Preclinical data show that therapeutic treatment with Auxora in a rat model of AKI improves kidney function as measured by glomerular filtration rate

LA JOLLA, Calif., Feb. 28, 2024 /PRNewswire/ — CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that data from its most recent preclinical study of Auxora™ (zegocractin) in acute kidney injury (AKI) will be presented in a poster and oral presentation at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) being held March 12-15, 2024 in San Diego, CA.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.